<SEC-DOCUMENT>0001157523-23-001086.txt : 20230714
<SEC-HEADER>0001157523-23-001086.hdr.sgml : 20230714
<ACCEPTANCE-DATETIME>20230714081021
ACCESSION NUMBER:		0001157523-23-001086
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230714
FILED AS OF DATE:		20230714
DATE AS OF CHANGE:		20230714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		231088070

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53456645.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: center;">For the month of July 2023</div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
      <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
      <div style="text-align: center;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="text-align: center;">Form 20-F&#160; &#9744; Form 40-F&#160; &#9746;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="text-align: justify;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="text-align: center;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zdf343f069c0b4400b4f314c866be46d3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 13%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 85%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div><a href="a53456645_ex991.htm">99.1</a></div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 85%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify;"><a href="a53456645_ex991.htm">Press Release dated July 14, 2023.</a></div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-top: 6pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; margin-top: 6pt; font-weight: bold;">SIGNATURE</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3f9f16bd6af3482a89862d5c12f6e7c9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
              <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Date: July 14, 2023</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-style: italic;">/s/ Brad McConn</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Brad McConn</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53456645_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--July 14, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other
            interested parties to participate in an upcoming interview hosted by Market Radius Research. </p>
          <p> Martin Gagel, founder of Market Radius Research, will join forces with Dr. Jennifer Bath, CEO of IPA, to delve into the intricate details of IPA's revolutionary platform. IPA&#8217;s patented technology seamlessly integrates multiple modalities of
            biological data, multi-omics modeling, and artificial intelligence, a unique capability within the field of biotherapeutic research. Additionally, the interview will shed light on IPA's in silico commercialization and market development
            strategies. </p>
          <p> The event will be presented as a dynamic and interactive online webinar, offering attendees the opportunity to engage with the Company in real-time by posing questions following the interview. For those unable to join the event live on the
            designated day, an archived webcast will be made accessible for later viewing. </p>
          <p> Don't miss this exclusive occasion to gain valuable insights into ImmunoPrecise Antibodies&#8217; groundbreaking advancements. Mark your calendars and join us on the webinar to witness the future of biotherapeutic research and development. </p>
          <p> <b>Event: </b>Radius Research Pitch, Deep Dive and Q&amp;A with ImmunoPrecise Antibodies </p>
          <p> <b>Presentation Date &amp; Time:</b> Wednesday, July 19th at 4 PM ET / 1 PM PT </p>
          <p> <b>Webcast Registration Link: </b>https://us02web.zoom.us/webinar/register/8216884929254/WN_PYpMINe_SyGVBG4uFxTmkg </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> The conference call will be webcast live and available for replay via a link provided in the Events section of the company&#8217;s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx </p>
          <p> Market Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional level discussion and Q&amp;A. Market Radius is hosted by Martin Gagel, former top-ranked technology analyst. By registering for
            this webinar, you agree to receive email communications from Market Radius Capital, Inc. and from the presenting company (with unsubscribe). Your email will not be further shared. Martin Gagel and Market Radius Capital, Inc. are not registered
            or licensed to provide investment advice and may own shares in mentioned companies and may be compensated for these services. Content is for information purposes only and is not advice or recommendations and may include incomplete or incorrect
            information. Investing entails a high degree of risk. This is a production of Market Radius Capital, Inc. </p>
          <p> <b>About ImmunoPrecise Antibodies Ltd</b> </p>
          <p> ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.
            (collectively, the &#8220;IPA Family&#8221;). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in
            bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics
            against the most challenging targets. For further information, visit www.ipatherapeutics.com. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Investors: investors@ipatherapeutics.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
